Abstract
The high level of manipulability of viral genome has set up HSV-1 to be an ideal viral vector for oncolytic virotherapy. In the past two decades, several oncolytic HSV-1 viruses have been successfully developed and assessed in animal studies. Accumulated evidences show that oncolytic HSV- 1 can efficiently infect many tumor cells and augment anti-tumor effect by induction of systemic innate and adaptive immune responses. Inspiring results have been accomplished in several phase I clinical trials for glioma, head and neck squeous cells carcinoma and Melanoma using oncolytic HSV- 1 viruses. More recently, oncovey, one of oncolytic HSV-1 viruses has been approved by FDA for the comprehensive evolution of its anti-tumor effects in phase III clinical trials. These promising studies encourage more efforts to be devoted to craft the new generation of oncolytic HSV-1. Herein, we will review and summarize the basic strategies to construct oncolytic HSV-1 viruses and their applications in cancer therapy.
Keywords: Anti-tumor, Oncotarget, Oncolytic HSV-1 virotherapy, ICP34.5, Glioma.
Current Gene Therapy
Title:Oncotarget Strategies For Herpes Simplex Virus-1
Volume: 16 Issue: 2
Author(s): Lumin Zhang, Tsurumi Tatsuya and Yukihiro Nishiyama
Affiliation:
Keywords: Anti-tumor, Oncotarget, Oncolytic HSV-1 virotherapy, ICP34.5, Glioma.
Abstract: The high level of manipulability of viral genome has set up HSV-1 to be an ideal viral vector for oncolytic virotherapy. In the past two decades, several oncolytic HSV-1 viruses have been successfully developed and assessed in animal studies. Accumulated evidences show that oncolytic HSV- 1 can efficiently infect many tumor cells and augment anti-tumor effect by induction of systemic innate and adaptive immune responses. Inspiring results have been accomplished in several phase I clinical trials for glioma, head and neck squeous cells carcinoma and Melanoma using oncolytic HSV- 1 viruses. More recently, oncovey, one of oncolytic HSV-1 viruses has been approved by FDA for the comprehensive evolution of its anti-tumor effects in phase III clinical trials. These promising studies encourage more efforts to be devoted to craft the new generation of oncolytic HSV-1. Herein, we will review and summarize the basic strategies to construct oncolytic HSV-1 viruses and their applications in cancer therapy.
Export Options
About this article
Cite this article as:
Zhang Lumin, Tatsuya Tsurumi and Nishiyama Yukihiro, Oncotarget Strategies For Herpes Simplex Virus-1, Current Gene Therapy 2016; 16 (2) . https://dx.doi.org/10.2174/1566523216666160331130153
DOI https://dx.doi.org/10.2174/1566523216666160331130153 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Emerging Adenoviral Vectors for Stable Correction of Genetic Disorders
Current Gene Therapy Chromosome 17 in Fronto Temporal Lobak Degeneration (FTLD): From MAPT to Progranulin and Back
Current Alzheimer Research MicroRNAs in Cancer Stem Cells: New Regulators of Stemness
Current Pharmaceutical Design Hibiscus Sabdariffa Linnaeus (Malvaceae), Curcumin and Resveratrol as Alternative Medicinal Agents Against Metabolic Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry A Key Role for Connexin Hemichannels in Spreading Ischemic Brain Injury
Current Drug Targets Targeting Glioblastoma Stem Cells: Cell Surface Markers
Current Medicinal Chemistry Fluorescence Imaging of Human Cells with a Novel Conjugate of the Antifungal Nystatin
Medicinal Chemistry A Critical Transcription Factor NF-κB as a Cancer Therapeutic Target and its Inhibitors as Cancer Treatment Options
Current Medicinal Chemistry A Comparison of Physicochemical Property Profiles of Marketed Oral Drugs and Orally Bioavailable Anti-Cancer Protein Kinase Inhibitors in Clinical Development
Current Topics in Medicinal Chemistry Systematic Analysis of RNAi Reports Identifies Dismal Commonality at Gene-Level and Reveals an Unprecedented Enrichment in Pooled shRNA Screens
Combinatorial Chemistry & High Throughput Screening 3-Carboranyl Thymidine Analogues (3CTAs) and Other Boronated Nucleosides for Boron Neutron Capture Therapy
Anti-Cancer Agents in Medicinal Chemistry Fibroblast Growth Factor Receptor Signaling in Cancer Biology and Treatment
Current Signal Transduction Therapy The Development of Ataxia Telangiectasia Mutated Kinase Inhibitors
Mini-Reviews in Medicinal Chemistry Magnetite Nanostructures with Applications in Cancer Therapy
Current Proteomics From Na+/K+-ATPase and Cardiac Glycosides to Cytotoxicity and Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Epigenetic Regulators Governing Cancer Stem Cells and Epithelial- Mesenchymal Transition in Oral Squamous Cell Carcinoma
Current Stem Cell Research & Therapy Application of Proteomic Tools in Modern Nanotechnological Approaches Towards Effective Management of Neurodegenerative Disorders
Current Drug Metabolism A Novel Approach to Refractory Epilepsy by Targeting Pgp Peripherally and Centrally: Therapeutic Targets and Future Perspectives
CNS & Neurological Disorders - Drug Targets Ring Finger Ubiquitin Protein Ligases and Their Implication to the Pathogenesis of Human Diseases
Current Pharmaceutical Design Overview of SLC22A and SLCO Families of Drug Uptake Transporters in the Context of Cancer Treatments
Current Drug Metabolism